Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
MA 2029 is a novel, selective and competitive motilin receptor antagonist, which inhibits motilin-induced intestinal contractions in animals models. MA 2029 may be useful for gastrointestinal disorders associated with disturbed gastrointestinal motility such as IBS.
您的位置：
